000			nab a22 7a 4500
999			_c16637 _d16637
003			PC16637
005			20211102133258.0
008			211102b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92616 _aLópez Muñoz, Francisco _eInstituto de Investigación i+12
245	0	4	_aThe effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. _h[revisión]
260			_bExpert review of neurotherapeutics, _c2014
300			_a14(6):593-605.
500			_aFormato Vancouver: Alamo C, López Muñoz F, García García P. The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder. Expert Rev Neurother. 2014 Jun;14(6):593-605.
501			_aPMID: 24779382
504			_aContiene 86 referencias
520			_aThe majority of patients with bipolar disorder spend a lot of time in depressive episodes that impose a great burden on patients, caregivers, and society and accounts for the largest part of the morbidity-mortality of the illness. Lurasidone is an atypical antipsychotic with a potent binding affinity as antagonist for D2, 5-HT2A, 5-HT7, and partial agonist at 5-HT1A receptors. Affinity for other receptors as H1 and muscarinic were negligible. Lurasidone was approved in 2010 for the treatment of schizophrenia and recently, 2013, for bipolar depression in monotherapy and an adjunct to lithium or valproate. Clinical trials have established that lurasidone adjuvant to lithium or valproate has more efficacy than the placebo and is associated with minimal weight gain and no clinically meaningful alterations in glucose, lipids, or the QT interval. Additional studies are desirable to know the clinical profile of lurasidone in long-term treatment, in patients with bipolar II disorders, and versus other antipsychotic agents.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16637.pdf _ySolicitar documento
942			_2ddc _cREV _n0